Alport Syndrome and Other Kidney Diseases

Reata is conducting a pivotal registrational Phase 2/3 study named CARDINAL to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease (CKD) caused by Alport syndrome. Alport syndrome is a rare and serious hereditary disease that affects approximately 12,000 people in the United States and 40,000 people globally. Alport syndrome is caused by mutations in the genes encoding type IV collagen, a major structural component of the glomerular basement membrane (GBM) in the kidney.

Patients with Alport syndrome are normally diagnosed with the disease in childhood to early adulthood and have average glomerular filtration rate (GFR) declines of 4.0 mL/min/1.73 m2 per year30. The progressive decline of GFR in Alport syndrome patients leads to renal failure and end-stage renal disease (ESRD). Fifty percent of males with the most prevalent subtype of Alport syndrome require dialysis or kidney transplant by age 25. The incidence of renal failure in these patients increases to 90% by age 40 and nearly 100% by age 6031. Similar to patients with other forms of CKD, Alport syndrome patients receiving dialysis are at increased risk for cardiovascular disease and infections, which are the most common causes of death in these patients. Currently, there are no approved therapies for the treatment of Alport syndrome.

Reata recently announced primary endpoint and other 12-week data from the ongoing open-label Phase 2 portion of the CARDINAL trial (click here for data presentation). The Phase 2 portion of the trial enrolled 30 patients, and available data demonstrate that bardoxolone methyl significantly increased kidney function in Alport syndrome patients as measured by estimated GFR (eGFR). From a mean baseline eGFR of 54 mL/min/1.73 m2, data from patients showed a mean increase of 13.4 mL/min/1.73 m2 at Week 12 (p<0.000000001). All patients demonstrated increases in eGFR, with 87% of patients demonstrating a clinically meaningful increase in eGFR of at least 4.0 mL/min/1.73 m2 by Week 12, and 63% of patients demonstrated an increase in eGFR of at least 10.0 mL/min/1.73 m2. Additionally, 73% of patients had an improvement in CKD stage, and none worsened. As of the 12-week primary endpoint visit for the Phase 2 portion, no discontinuations or serious adverse events (SAEs) were reported, and reported adverse events (AEs) were generally mild to moderate in intensity.

In August 2017, Reata began enrolling patients in the Phase 3 portion of CARDINAL, and the company expects data from the study in the second half of 2019. Reata recently received orphan drug designation for bardoxolone methyl for the treatment of Alport syndrome. Bardoxolone methyl’s novel anti-inflammatory mechanism of action and clinical activity in Alport syndrome and diabetic CKD encourage the study of bardoxolone methyl in additional, rare kidney diseases. PHOENIX is an open-label, multi-center Phase 2 trial to evaluate the safety and efficacy of bardoxolone methyl in patients with autosomal dominant polycystic kidney disease (ADPKD), IgA nephropathy, type 1 diabetic CKD, or focal segmental glomerulosclerosis (FSGS). We have enrolled patients in PHOENIX from each of the four rare forms of CKD, and expect to have data from one or more of the four cohorts available during the second half of 2018.

For an overview of Reata’s development program in CKD see this presentation.

How does bardoxolone methyl target pathogenic pathways in CKD?

Bardoxolone methyl was originally considered for development in cancer patients, and in two Phase 1 studies in cancer, bardoxolone methyl reduced serum creatinine levels, corresponding to an increase in eGFR. Since then, Reata and collaborators have extensively characterized the effects of bardoxolone methyl on the kidney (150+ published papers). Both acute and chronic kidney disease, regardless of initiating cause (infection, diabetes, hypertension, autoimmunity), have inflammation and immune activation in common1. Bardoxolone methyl targets these common inflammatory pathways that are implicated in CKD.

Bardoxolone methyl activates molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone methyl binds to Keap1 and consequently activates Nrf2, a transcription factor that promotes normal mitochondrial function by making reducing equivalents available for ATP production, and increases cellular antioxidant content. This reduces mitochondrial reactive oxygen species (ROS) production and ROS-mediated activation of inflammatory signaling complexes. Binding to Keap1 and activation of Nrf2 also inhibit NF-κB, the primary transcription factor producing proteins that promote inflammation and the production of ROS.

In the kidney, the first stage of the blood filtering process takes place in the glomerulus, which consists of a small tuft of capillaries containing endothelial cells, between which are large pores, and mesangial cells which are modified smooth muscle cells that lie between the capillaries. Tight coordination between these cell types is necessary for proper filtration. The pores between the endothelial cells allow for the free filtration of fluid, plasma solutes, and protein. When endothelial cells become dysfunctional, due to oxidative stress or other reasons, the pores can become more permeable and increase spillage of protein, which can drive further inflammatory signaling and oxidative stress. The mesangial cells regulate blood flow by their contractile activity, and contraction of the cells reduces surface area for filtration of the blood. Mesangial cells also remove proteins and other molecules trapped in the glomerular basement membrane, or filtration barrier.

In preclinical models, bardoxolone methyl reverses endothelial dysfunction and chronic, disease-related mesangial cell contraction, resulting in increased surface area of the glomerulus and increased GFR. Additionally, bardoxolone methyl inhibits activation of inflammatory and pro-fibrotic pathways that lead to structural remodeling and glomerulosclerosis.

As a result, bardoxolone methyl and closely related structural analogs have been shown to improve renal function, reduce inflammation, and prevent injury, remodeling, and fibrosis, or the thickening and scarring of connective tissue, in a number of animal models of renal injury and disease2-6. Importantly, these increases in GFR were not due to effects on blood pressure, renal plasma flow, or pressure within the kidney in animals5.

Further, data from animal models relevant to chronic renal disease demonstrate that the compounds are anti-fibrotic and have protective effects on the renal interstitium, part of the extravascular space of the kidney responsible for modulating exchange among the tubular and vascular elements of the organ. Bardoxolone methyl and related analogs are protective in response to high protein, pressure overload in the setting of hyperfiltration2, increased kidney filtration driven by higher blood pressure, and dyslipidemia7, an abnormal amount of lipids in the blood.

How is it known that the increases in eGFR with bardoxolone methyl are reflective of true increases in GFR?

Clinical Trials of Bardoxolone Methyl in CKD

Bardoxolone methyl has been evaluated in multiple clinical trials enrolling over 2,000 patients exposed to active drug, including those with CKD caused by type 2 diabetes, PAH patients, Alport syndrome patients, patients with solid tumors or lymphoma, and healthy volunteers. Bardoxolone methyl has been shown to consistently improve kidney function as measured by eGFR and other markers of kidney function in numerous clinical trials. Key features of bardoxolone methyl’s effects on kidney function are summarized below.

Bardoxolone Methyl Improves Kidney Function as Assessed by eGFR, Measured GFR (Inulin Clearance), and Creatinine Clearance

In addition to eGFR improvements, bardoxolone methyl treatment has been shown to significantly increase directly-measured GFR in patients with type 2 diabetes and CKD using the “gold standard” inulin clearance method and to reduce the levels of blood waste products filtered by the kidney. In 2017, our partner, KHK, presented results of its trial, TSUBAKI, a double-blind, randomized, placebo-controlled Phase 2 trial conducted in Japan. In TSUBAKI, bardoxolone methyl demonstrated statistically significant and clinically meaningful increases in directly-measured GFR. Moreover, measured GFR increases were significantly and positively correlated with improvements in eGFR. The observed increase in GFR demonstrates that increases in eGFR produced by bardoxolone methyl in various forms of CKD, including Alport syndrome, reflect a true increase in kidney function. In TSUBAKI, bardoxolone methyl demonstrated a favorable safety profile with no adverse effect on blood pressure, urine output or sodium excretion, and no evidence of overt fluid overload or cardiac toxicity.

Are the increases in eGFR from bardoxolone methyl sustained?

Bardoxolone Methyl Demonstrated Sustained eGFR Increases for One and Two Years in Duration

Two separate trials in patients with CKD caused by type 2 diabetes, BEAM and BEACON, showed that increases in eGFR in patients treated for one year or longer with bardoxolone methyl, were sustained for at least one year. In BEACON, bardoxolone methyl treated patients had mean increases in eGFR through Week 48 of 5.6 mL/min/1.73 m2. In contrast, placebo-treated patients experienced a mean decline in eGFR of -1.2 mL/min/1.73 m2, corresponding to a statistically significant relative difference between groups of 6.8 mL/min/1.73 m2 (p<0.001). In BEAM, bardoxolone methyl treated patients at the mid- and high doses had mean increases in eGFR through Week 48 of 14.9 mL/min/1.73 m2. In contrast, placebo-treated patients experienced a mean decline in eGFR of -1.1 mL/min/1.73 m2, corresponding to a statistically significant relative difference between groups of 16.0 mL/min/1.73 m2 (p<0.001).

In February 2018, we announced that improvements in kidney function were durable for two years in LARIAT. These data represented the longest analyzed duration patients have received bardoxolone methyl. Patients in the placebo-controlled, double-blind phase of LARIAT had impaired kidney function upon study entry, with an average eGFR of 73.4 mL/min/1.73 m2. Patients who received treatment with bardoxolone methyl (n=71) had a statistically significant increase in eGFR compared to placebo (n=30) of 10.6 mL/min/1.73 m2 (p<0.0001) after 16 weeks of treatment. After completing 16 weeks of treatment, all patients in LARIAT were eligible to receive bardoxolone methyl in an open-label extension study. At the time of the analysis, 56 patients had received at least 56 weeks of bardoxolone methyl treatment, of which 55 had an eGFR measurement at Week 56. After 56 weeks of treatment, data demonstrated a statistically significant, mean increase in eGFR of 10.7 mL/min/1.73 m2 from baseline (p<0.0001). Additionally, 26 patients had received bardoxolone methyl for at least 104 weeks, and after 104 weeks of treatment, data demonstrated a statistically significant, mean increase in eGFR of 11.3 mL/min/1.73 m2 from baseline (p<0.0001). Notably, 88% of patients on bardoxolone methyl maintained increases in eGFR above baseline after two years of treatment.

PAH patients experience an estimated annual loss of kidney function of approximately 8 to 13 mL/min/1.73 m2 and are extremely sensitive to any adverse perturbations of renal or cardiac function. Additionally, the median survival for PAH patients from time of diagnosis is four to seven years. Upon study entry, the LARIAT PAH patients had a median time since diagnosis of 3.3 years (n=101; 66 weeks median duration of treatment). At the time of this analysis, LARIAT PAH patients had experienced a lower rate of hospitalization when compared to recent registrational and observational PAH studies, and there were no deaths among these LARIAT PAH patients.

Bardoxolone Methyl Significantly Reduced the Risk of Adverse Renal Events Validated to Predict Kidney Failure

In January 2018, a paper was published in the American Journal of Nephrology that included a characterization of bardoxolone methyl’s efficacy and longer-term effects on kidney function in BEACON. In this study, post-hoc analysis showed that patients randomized to bardoxolone methyl were significantly less likely to experience adverse kidney outcomes as defined by a composite renal endpoint consisting of ≥30% decline from baseline in eGFR, eGFR <15 mL/min/1.73 m2, or ESRD events (p<0.0001). This composite endpoint has recently been validated by a joint FDA, European Medicines Agency (EMA), and the National Kidney Foundation working group. Furthermore, bardoxolone methyl treatment resulted in a decreased number of kidney-related SAEs and ESRD events. The authors concluded that bardoxolone methyl preserves kidney function and may delay the onset of kidney failure in patients with type 2 diabetes and stage 4 CKD.

Bardoxolone Methyl Produces a Retained eGFR Benefit after Withdrawal of Drug

To further assess whether increases in eGFR from bardoxolone methyl treatment have the potential to delay or prevent ESRD and the need for dialysis or a transplant over the long term, we conducted a retained benefit analysis in the BEAM and BEACON clinical trials. In those trials, after patients had been treated with bardoxolone methyl or placebo for approximately one year, the drug was withdrawn for four weeks, and the post-withdrawal eGFR was compared to the patient’s baseline eGFR. Bardoxolone methyl and any active metabolites are eliminated from the body within approximately 10 days after withdrawal, so we believe the post-withdrawal eGFR change is a measure of the effect of long term bardoxolone methyl treatment on the structure of the kidney and its disease-modifying potential.

Importantly, in both BEAM and BEACON, bardoxolone methyl treatment produced a statistically significant improvement in retained eGFR versus placebo after withdrawal of drug. Also, the acute increase in eGFR from bardoxolone methyl treatment observed at 12 weeks was predictive of both the on-treatment and retained eGFR benefit after one year of treatment. This finding is important because it indicates that increases in eGFR from a relatively short, 12 week, treatment periods with bardoxolone methyl may be predictive of a long term clinical benefit.

How can bardoxolone methyl affect kidney function in patients with Alport syndrome?

Bardoxolone methyl has the potential to address the causes of GFR loss in Alport syndrome patients because it activates molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting ROS-mediated pro-inflammatory signaling. There are no currently approved therapies for the treatment of CKD caused by Alport syndrome. The goal of current disease management is to slow the progression of CKD, beginning with anti-hypertensives, such as angiotensin converting enzyme inhibitors or angiotensin receptor blockers, aldosterone, and diuretics, all of which are intended to reduce the levels of protein found in patient urine. Once patients reach ESRD, they require dialysis or renal transplantation.

During 2016, we sought and received guidance from the FDA on key elements of a single, pivotal Phase 2/3 clinical trial that would study the safety and efficacy of bardoxolone methyl in patients with CKD caused by Alport syndrome. Our clinical study in chronic kidney disease caused by Alport syndrome, named CARDINAL, was initiated in February of 2017, and is enrolling patients in the Phase 3 portion of the study. CARDINAL is an international, multi-center, double-blind, randomized, placebo-controlled Phase 2/3 trial studying the safety and effectiveness of bardoxolone methyl in patients with Alport syndrome. The trial is enrolling patients from age 12 to 60 with eGFR values between 30 to 90 mL/min/1.73 m2. The Phase 2 portion of the study is open-label, and the primary endpoint assesses eGFR change at 12 weeks. These Phase 2 patients will not be included in the Phase 3 portion of the trial.

The Phase 2 portion of the study met its primary efficacy endpoint and showed that bardoxolone methyl increased eGFR by 13.34 mL/min/1.73 m2 (n=30, p<0.0000000015, 95% CI 10.54 to 16.3) after 12 weeks of treatment. All patients completed the treatment period without any discontinuations. The increases in eGFR were consistent across multiple subgroups, including age, gender, baseline albuminuria, and CKD stage, and all patients had increases from baseline. Notably, 87% had an increase of at least 4 ml/min/1.73 m2, which is the approximate annual rate of decline in kidney function in patients with Alport syndrome. The improvements in eGFR translated to an improvement in CKD stage for 22/30 (73%) patients. No serious adverse events or discontinuations were reported, and adverse events were generally mild to moderate in intensity.

The Phase 3 portion of CARDINAL is designed to support registration and will randomize approximately 150 patients evenly to either bardoxolone methyl or placebo. The Phase 3 primary efficacy endpoint is the change from baseline in eGFR in bardoxolone methyl-treated patients relative to placebo after one year. The eGFR change after 48 weeks will be measured while the patients are on treatment, and the key secondary endpoints will be the change from baseline in eGFR after withdrawal of drug for four weeks (retained eGFR) after one year. After the initial withdrawal, patients will be restarted on study drug with their original treatment assignments and will continue study drug for a second year. The eGFR change at two years will also be measured after 100 weeks while the patient is on treatment and after withdrawal of drug for four weeks (retained eGFR). Based on FDA guidance, if the trial is positive, the year one retained eGFR data could support accelerated approval under subpart H of the Food, Drug, and Cosmetic Act, and the year two retained eGFR data could support full approval.

What happened in BEACON and how can the risk of acute fluid retention be managed?

BEACON was a large Phase 3 trial designed to meet FDA requirements that bardoxolone methyl delay the time to ESRD or death. It was conducted in only advanced (Stage 4) CKD patients because earlier stage patients would not have contributed to the ESRD endpoint. The BEACON trial was terminated in 2012 for safety concerns in response to a recommendation from the independent data monitoring committee, which identified a significant increase in the risk of heart failure hospitalizations or death from heart failure with bardoxolone methyl treatment (96 [8.8%] bardoxolone methyl-treated patients versus 55 [5.0%] placebo patients)9.


After BEACON was terminated, analyses revealed the following:

(a) the primary reason for the increase in adjudicated heart failure events in the treatment group was fluid overload (not direct cardiotoxicity),

(b) patients at risk, on average, were in subclinical heart failure prior to randomization (mean baseline BNP 550 pg/mL), and

(c) the imbalance in events occurred only in the first four weeks after randomization10.


The profile of fluid overload in BEACON was similar to that previously observed in CKD patients with the endothelin receptor antagonist, avosentan (ASCEND study). Urinary protein induces endothelin signaling and vasoconstriction in Stage 4 and 5 CKD patients and bardoxolone methyl has been shown to modulate endothelin signaling in kidneys10. Because endothelin signaling is dysregulated in the kidneys of patients with lower eGFR values, acute modulation of this pathway by bardoxolone methyl in a Stage 4 CKD patient population may have promoted acute sodium and water retention, which translated to frank fluid overload in susceptible patients. Urinary data from BEACON and a separate Phase 2 study showed sodium and volume retention in Stage 4 but not Stage 3 CKD patients10.

Post hoc analysis identified two risk factors that are predictors of fluid overload events: elevated baseline B-type natriuretic peptide (BNP) and prior hospitalization for heart failure11. Patients in BEACON without these risk factors showed no imbalance in heart failure events or mortality, which is consistent with early Phase 1 and Phase 2 clinical studies that primarily enrolled CKD stage 3 patients who had better baseline kidney function and less cardiovascular disease12,13. Exclusion of at-risk patients also improved the distribution of ESRD, primary composite events, and SAEs in BEACON11. (See Late-Breaking Presentation at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress in Amsterdam in June 2014, Investigation of Serious Adverse Events in Bardoxolone Methyl Patients in BEACON, that discusses the clinical profile, risk factors, and likely mechanistic explanation of key adverse events uncovered in the BEACON trial.)

Using the identified risk factors for heart failure from BEACON, patients with elevated BNP and prior history of heart failure are excluded from ongoing and future studies of bardoxolone methyl. In addition, more frequent visits during the first few weeks of treatment, additional assessment of BNP, and daily monitoring of weight is used to assess for signs and symptoms of fluid overload. These risk mitigation features have been implemented in clinical programs with bardoxolone methyl that have enrolled approximately 500 patients, which have not shown increased risk for fluid overload to date.

What other findings have been observed in clinical trials with bardoxolone methyl?

Throughout the on-going clinical development of bardoxolone methyl, some clinical observations have been observed repeatedly in multiple studies. Preclinical studies have been conducted to investigate and help understand these clinical findings, and a summary of clinical observations and supporting preclinical data is provided below.

  1. Decreased body weight

    Some patients in prior clinical trials of bardoxolone methyl have lost weight during the trials. When observed, weight reduction with bardoxolone methyl tended to be more pronounced in patients with higher body mass index (BMI)19 and correlated with reductions in waist circumference20. Multiple preclinical studies have demonstrated that bardoxolone methyl reduces fat production and promotes break-down (beta-oxidation) of fat to be used as fuel for energy production. These effects are associated with improved blood sugar control, reduced fat, and preservation of muscle mass in animals16-18. We hypothesize that similar effects may be associated with the weight loss observed in some clinical trial participants. Moreover, creatinine is a by-product of muscle metabolism, and its excretion is associated with muscle wasting. In clinical trials with bardoxolone methyl, urinary creatinine levels were generally unchanged, suggesting that the observed weight loss was not caused by muscle wasting12.

  2. Increased proteinuria

    Increases in urinary protein have been observed in CKD patients treated with bardoxolone methyl in previous clinical trials. In CKD, damage to the glomerular filtration barrier results in loss of selectivity, increased filtration of protein, and subsequent proteinuria. When GFR increases, the increased flow delivers more albumin to proximal tubules and decreases protein reabsorption in tubules21. Because most water is reabsorbed and urine volume is generally constant, the increased protein is shunted to the same urinary volume, thereby increasing the urinary albumin concentration in a manner that does not reflect further loss of filtration selectivity. The increases in urinary protein that have been observed in CKD patients treated with bardoxolone methyl in clinical trials are consistent with the increases in flow and GFR9. The increases in proteinuria are significantly correlated with eGFR increases. Moreover, when normalized by eGFR, the amount of excreted urinary protein is unchanged from baseline22. The increases in proteinuria with bardoxolone methyl have not been associated with other signs of kidney injury. These clinical observations are consistent with data from animal models of protein overload-induced secondary nephropathy, where bardoxolone methyl has shown a protective effect4.

  3. Increases in transaminases (LFT)

    In clinical trials, transaminase increases with bardoxolone methyl have been observed that are transient and reversible, with a clinical pattern that is distinct from that observed with liver injury. The transaminases ALT and AST are enzymes that are measured in the blood to assess liver function and are often referred to as LFTs. Transaminases, including ALT and AST, also play a critical role in cellular energy metabolism, and are produced in many organs, including the liver, kidney, muscle, and others23. The biological target of bardoxolone, Nrf2, has been shown to regulate cellular production of transaminases in liver and other tissues, such as kidney, muscle, and colon tissue, and their production is increased in response to bardoxolone methyl24. In clinical trials, bardoxolone methyl was not associated with any other signs of liver injury, and there have been no reports of severe liver injury or failure (Hy’s Law cases). In animal models, bardoxolone methyl and close analogs are protective against liver injury25-27.

  4. Decrease in serum magnesium

    Decreases in the levels of the enzyme creatine kinase have been observed with bardoxolone methyl in some clinical trials. Magnesium is an element that is used in tissues for energy metabolism, and it is also found at much lower concentrations in the blood. Both creatine kinase and magnesium are necessary in the conversion of ATP to ADP for the production and maintenance of the body’s energy supply. We hypothesize that decreases in magnesium in the blood may reflect an intracellular shift to higher energy-demanding cells, such as muscle cells. Correlations between magnesium and creatine kinase decreases in patients may therefore reflect improved muscle metabolism.

    Importantly, unchanged excretion of magnesium in the urine and excretion of other electrolytes suggest that decreases in serum magnesium are not due to kidney problems (i.e., renal magnesium wasting or tubular toxicity). Unchanged magnesium levels in sublingual epithelial cells also support the hypothesis that total body magnesium depletion does not occur. Decreases in magnesium have not been associated with increased stomach or cramping side effects28. Decreases in magnesium with bardoxolone have also not been associated with irregular heart rhythms (as assessed by changes in the QT interval). In a cardiovascular safety study, bardoxolone methyl did not increase the QT interval at doses as high as 80 mg.

  5. Muscle spasms

    Muscle spasms are the most commonly reported side effect reported in clinical trials with bardoxolone methyl. Similar muscle spasms have been reported with insulin treatment in diabetics. In vitro, a bardoxolone methyl analog increased the conversion of glucose to energy in cultured muscle cells29. Thus, the etiology and clinical profile of the muscle spasms in patients treated with bardoxolone methyl may be similar to exercise-induced muscle cramps. Importantly, the spasms observed in clinical trials have not been associated with increased markers of muscle toxicity, such as lactate dehydrogenase, which is released during tissue damage, or increases in other serum electrolytes such as phosphorous or potassium levels. Instead, decreases in the levels of the enzyme creatine kinase have been observed in multiple trials with bardoxolone methyl, which is consistent with improved muscle metabolism.

Is bardoxolone methyl being studied in other forms of CKD?

The inflammatory processes that promote disease progression in diabetic CKD and Alport syndrome are similar to those underlying other forms of CKD. Bardoxolone methyl’s novel anti-inflammatory mechanism of action and clinical activity in Alport syndrome and diabetic CKD therefore encourage the study of bardoxolone methyl in additional, rare kidney diseases. Similar to the Phase 2 portion of the CARDINAL study of bardoxolone in CKD caused by Alport syndrome, PHOENIX will be an open-label trial of bardoxolone orally-administered once-daily for 12 weeks, with a primary efficacy endpoint of change from baseline in the eGFR at week 12. The PHOENIX study will enroll patients with autosomal dominant polycystic kidney disease, IgA nephropathy, CKD associated with type 1 diabetes and focal segmental glomerulosclerosis, with approximately 25 patients enrolled per cohort. We have enrolled patients in PHOENIX from each of the four rare forms of CKD, and expect to have data from one or more of the four cohorts available during the second half of 2018.

References

  1. Imig, J.D. & Ryan,M.J. Immune and inflammatory role in renal disease. Compr. Physiol 3, 957-976 (2013).
  2. Aminzadeh, M.A. et al. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease. Xenobiotica(2013).
  3. Hisamichi, M. et al. Role of bardoxolone methyl, a nuclear factor erythroid 2-related factor 2 activator, in aldosterone- and salt-induced renal injury. Hypertens. Res.(2017).
  4. Zoja C, Corna D, Locatelli M, et al. Targeting Keap1-Nrf2 Pathway Ameliorates Renal Inflammation and Fibrosis in Mice with Protein-Overload Proteinuria. Poster (TH-PO717) American Society of Nephrology Meeting, 2010. Reproduced here with permission of ASN.
  5. Ding, Y. et al. The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells. Kidney Int. 83, 845-854 (2013).
  6. Wu, T. et al. Prevention of murine lupus nephritis by targeting multiple signaling axes and oxidative stress using a synthetic triterpenoid. Arthritis Rheumatol. 66, 3129-3139 (2014).
  7. Camer, D. et al. Bardoxolone methyl prevents the development and progression of cardiac and renal pathophysiologies in mice fed a high-fat diet. Chem. Biol. Interact. 243, 10-18 (2016).
  8. Agodoa, L.Y. et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285, 2719-2728 (2001).
  9. de Zeeuw, D. et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 369, 2492-2503 (2013).
  10. Chin, M.P. et al. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am. J. Nephrol. 39, 499-508 (2014).
  11. Chin, M.P. et al. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J. Card Fail. 20, 953-958 (2014).
  12. Pergola, P. et al. Effect of Bardoxolone on Kidney Function in Patients with T2D and Stage 3b – 4 CKD. Am J Nephrol. 33, 469-476 (2011).
  13. Pergola, P.E. et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J Med. 365, 327-336 (2011).
  14. Inker, L.A. et al. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials. Am. J. Kidney Dis. 64, 848-859 (2014).
  15. Levey, A.S. et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am. J. Kidney Dis. 64, 821-835 (2014).
  16. Saha, P.K., Reddy, V.T., Konopleva, M., Andreeff, M., & Chan, L. The triterpenoid CDDO-Me has potent antidiabetic effects in diet-induced diabetic mice and Leprdb/db mice. J. Biol. Chem.(2010).
  17. Shin, S. et al. Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-Imidazolide. Eur. J. Pharmacol.(2009).
  18. Dinh, C.H. et al. Bardoxolone Methyl Prevents Mesenteric Fat Deposition and Inflammation in High-Fat Diet Mice. ScientificWorldJournal. 2015, 549352 (2015).
  19. Pergola, P. et al. Weight Loss in Stage 3b and 4 CKD Patients with Type 2 Diabetes given Bardoxolone Methyl. Presentation. ERA-EDTA Meeting. Paris, France(2012).
  20. Meyer, C. et al. Investigation of Serious Adverse Events in Bardoxolone Methyl Patients in BEACON. Presentation. ERA-EDTA Meeting. Amsterdam, Netherlands(2014).
  21. Lazzara, M.J. & Deen, W.M. Model of albumin reabsorption in the proximal tubule. Am. J. Physiol Renal Physiol 292, F430-F439 (2007).
  22. Rossing, P. et al. Bardoxolone Methyl and Albuminuria in Type 2 Diabetes Patients with CKD. Poster. American Society of Nephrology Meeting(2012).
  23. Felig, P. The glucose-alanine cycle. Metabolism 22, 179-207 (1973).
  24. Miller, G. et al. Bardoxolone Methyl Transcriptionally Regulates Transaminase Levels and Increases Glutathione Levels. Poster. American Society of Nephrology (ASN)(2011).
  25. Yates, M.S. et al. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole. Cancer Res 66:2488-94 (2006).
  26. Reisman, S.A., Buckley, D.B., Tanaka, Y., & Klaassen, C.D. CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes. Toxicol. Appl. Pharmacol. 236, 109-114 (2009).
  27. Osburn, W.O. et al. Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice. Toxicol. Sci. 104, 218-227 (2008).
  28. Chin, M. et al. Bardoxolone Methyl Acutely Reduces Serum Magnesium in Stage 3b and 4 CKD Patients with Type 2 Diabetes without any Adverse Effect on QT Interval. Presentation. ERA-EDTA Meeting. Paris, France(2012).
  29. Stidham, R. et al. Antioxidant Inflammation Modulators (AIMs) Increase Glucose Metabolism in Muscle Cells. Poster. American Society of Nephrology Meeting(2011).
  30. Rheault, M. et al. Change in Glomerular Filtration Rate and Renal Biomarkers in Patients with Chronic Kidney Disease Due to Alport syndrome: Interim Results from the ATHENA Study, a Prospectively Designed Natural History Study. Nephrol. Dial. Transplant. 31, i126 (2016).
  31. Jais, J.P. et al. X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J. Am. Soc. Nephrol. 11, 649-657 (2000).